Galera Therapeutics, Inc.

Galera Therapeutics, Inc. is a biopharmaceutical company that has shifted its strategic focus to developing a product candidate to treat certain types of advanced breast cancer. Historically, the company focused on developing small molecule superoxide dismutase (SOD) mimetics to improve radiotherapy in cancer by reducing severe oral mucositis (SOM). In October 2025, Galera sold its assets related to avasopasem, rucosopasem, and all other dismutase mimetics assets to Biossil, Inc., a privately-held company based in Toronto, Canada. Galera received an upfront payment of $3.5 million from Biossil and is eligible for further payments upon achieving future regulatory and commercial milestones, along with contingent value rights of up to $105.0 million in aggregate. On December 30, 2024, Galera acquired Nova Pharmaceuticals, Inc., a privately-held biotechnology company advancing a pan-inhibitor of nitric oxide synthase (NOS). This acquisition led to the company's new focus on developing a product candidate for advanced breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). Following the sale to Biossil, Galera's portfolio now consists of a pan-NOS inhibitor. The lead program is a Phase 1/2 trial of the pan-NOS inhibitor in combination with nab-paclitaxel and alpelisib for MpBC. This investigator-sponsored trial is funded by a National Institutes of Health (NIH) grant to investigators at the Methodist Hospital in Houston, Texas, which also includes the drug supply for the trial. Galera Therapeutics, Inc. common stock is listed on the Over-The-Counter Quote Bulletin Board - Venture Market (OTCQB: GRTX).